Drug Trial Radar · NCT03197818
Active Controlled Trial of CHF5993 Pressurized Metered-dose Inhaler ( pMDI) vs Symbicort®Turbuhaler® in Patients With Chronic Obstructive Pulmonary Disease ( COPD) (TRIVERSYTI)
Last checked: Nov 20, 2026Latest source record: Jul 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
708
Actual
Start
Dec 14, 2016
Primary completion
May 26, 2020
Study completion May 26, 2020
Sponsor
- Lead sponsor
- Chiesi Farmaceutici S.p.A.Industry
- Sponsor type
- Industry
- First posted
- Jun 23, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objective • To demonstrate the superiority of CHF 5993 pressurised metered dose inhaler (pMDI) over Symbicort® Turbuhaler® in terms of pulmonary function (change from baseline in pre-dose morning forced expiratory volume in the first second of a forced vital capacity manoeuvre \[FEV1\] and 2-hour post-dose morning FEV1 at Week 24). Secondary Objectives Key secondary objective: • To demonstrate the superiority of CHF 5993 pMDI over Symbicort® Turbuhaler® in terms of pulmonary function (change from baseline in pre-dose morning FEV1 and 2-hour post-dose morning FEV1 at Week 24) in the subgroup of Chinese population. Other secondary objectives: * To evaluate the effect of CHF 5993 pMDI on other lung function parameters, patient's health status and clinical outcome measures; * To collect data in order to assess the impact of study treatments on health economic outcomes; * To assess the safety and the tolerability of the study treatments.
Conditions
- COPD (Chronic Obstructive Pulmonary Disease)
Interventions
CHF 5993 100/6/12.5 µgDrug
Fixed combination of extrafine beclometasone dipropionate 100 µg plus formoterol fumarate 6 µg plus glycopyrronium bromide 12.5 µg / metered dose
160 µg budesonide + 4.5 µg formoterol fumarateDrug
Fixed combination of budesonide 160 µg plus formoterol fumarate 4.5 µg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Pre-dose Forced Expiratory Volume Within the First Second (FEV1) at Week 24Time frame: Week 24 (Visit 6)
- Change From Baseline in 2-hour Post-dose FEV1 at Week 24Time frame: Week 24 (Visit 6)
Locations
64 sites in 3 countries. Site status is shown where the registry gives one.
Chiesi Clinical Trial Site 156001
Guangzhou, China
Chiesi clinical Trial Site 156031
Beijing, Beijing Municipality, China
Chiesi Clinical Trial Site 156026
Beijing, Beijing Municipality, China
Chiesi clinical Trial Site 156017
Beijing, Beijing Municipality, China
Chiesi Clinical Trial Site 156012
Beijing, Beijing Municipality, China
Chiesi Clinical Trial Site 156045
Chongqing, Chongqing Municipality, China
Chiesi Clinical Trial Site 156002
Fuzhou, Fujian, China
Chiesi clinical Trial Site 156024
Foshan, Guangdong, China
Chiesi Clinical Trial Site 156048
Guangzhou, Guangdong, China
Chiesi Clinical Trial Site 156013
Guangzhou, Guangdong, China
Chiesi Clinical Trial Site 156008
Zhanjiang, Guangdong, China
Chiesi Clinical Trial site 156003
Nanning, Guangxi, China
Chiesi clinical Trial Site 156020
Haikou, Hainan, China
Chiesi Clinical Trial Site 156044
Shijiangzhuang, Hebei, China
Chiesi Clinical Trial Site 156040
Changsha, Hunan, China
Chiesi Clinical Trial Site 156043
Baotou, Inner Mongolia, China
Chiesi Clinical Trial Site 156015
Baotou, Inner Mongolia, China
Chiesi Clinical Trial Site 156004
Huai'an, Jiangsu, China
Chiesi clinical Trial Site 156033
Jiangyin, Jiangsu, China
Chiesi clinical Trial Site 156022
Nanjing, Jiangsu, China
Chiesi Clinical Trial Site 156047
Jiujiang, Jiangxi, China
Chiesi Clinical Trial Site 156041
Nanchang, Jiangxi, China
Chiesi clinical Trial Site 156028
Nanchang, Jiangxi, China
Chiesi Clinical Trial Site 156042
Pingxiang, Jiangxi, China
Chiesi clinical Trial Site 156023
Changchun, Jilin, China
Chiesi Clinical Trial Site 156036
Changchun, Jilin, China
Chiesi clinical Trial Site 156019
Changchun, Jilin, China
Chiesi Clinical Trial Site 156007
Shenyang, Liaoning, China
Chiesi clinical Trial Site 156025
Yinchuan, Ningxia, China
Chiesi Clinical Trial Site 156014
Shanghai, Shanghai Municipality, China
Chiesi clinical Trial Site 156037
Shanghai, Shanghai Municipality, China
Chiesi Clinical Trial Site 156005
Shanghai, Shanghai Municipality, China
Chiesi Clinical Trial Site 156006
Shanghai, Shanghai Municipality, China
Chiesi Clinical Trial Site 156011
Shanghai, Shanghai Municipality, China
Chiesi Clinical Trial Site 156038
Shanghai, Shanghai Municipality, China
Chiesi Clinical Trial Site 156039
Taiyuan, Shanxi, China
Chiesi clinical Trial Site 156035
Chengdu, Sichuan, China
Chiesi Clinical Trial Site 156010
Chengdu, Sichuan, China
Chiesi clinical Trial Site 156032
Chongqing, Sichuan, China
Chiesi clinical Trial Site 156034
Tianjin, Tianjin Municipality, China
Showing 40 of 64 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.